Infliximab, etanercept and adalimumab can induce remission and prevent both clinical and radiological disease progression in rheumatoid arthritis with significant improvement in patients' symptoms ...

Index cases were 44 patients whose infliximab doses had been increased. Controls were patients treated with infliximab without dose increase (n = 44), and patients treated with etanercept (n = 36).

The cost per ACR50/70 response ratio favored the labeled dose of etanercept compared with both the low (3 mg/kg every 8 weeks) and high (10 mg/kg every 4 weeks) maintenance doses of infliximab.

This article explores the complex roles of cytokine networks in the development and progression of autoimmune diseases.

Celltrion Healthcare’s subcutaneous (SC) formulation of its infliximab biosimilar, codenamed CT-P13 SC, looks set to launch in Europe in the coming months in rheumatoid arthritis, after a ...

Now that the likes of Remicade (infliximab), Enbrel (etanercept) and, most importantly, Humira (adalimumab) have to compete with biosimilar versions, the NHS is grappling with how to make the most ...

We investigated whether patients with inflammatory bowel disease treated with infliximab have attenuated serological responses to a single dose of a SARS-CoV-2 vaccine. Design Antibody responses and ...

There is a simple discount patient access scheme for spesolimab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...